Company intelligence / Profile preview

Sanwa Holdings

Hong Kong Science Park, Sha Tin, Hong Kongsanwa-hldgs.co.jp ↗

Ownership: Public · 5929
Employees: ~41
Development stage: Commercial

Overview

Sanwa BioTech develops and commercializes microfluidic Lab-On-Chip platforms for rapid point-of-care diagnostics. Their immunoassay systems and test kits are used to detect pathogen infections quickly and accurately. The company holds ISO13485 certification for medical device quality management. Revenue in the most recent year was $8.1 million with approximately 41 employees.

Therapeutic areas: Infectious Diseases
Modalities: Diagnostic ToolsPoint Of Care DiagnosticsIn Vitro DiagnosticsMicrofluidics-based platform (Lab-On-Chip)
Industry: Protein Biomarker Diagnostics

Beyond the preview

Go deeper on Sanwa Holdings.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sanwa Holdings.

Explore the full profile